Transdermal estradiol reduces F2α-isoprostane levels in postmenopausal women

Menopause

Volumn 15, Issue 4, 2008, Pages 714-717

  Hermenegildo, Carlos ^a   Oviedo, Pilar J ^a   Laguna, Andrés ^a   García Pérez, Miguel Angel ^a   Tarín, Juan J ^a   Cano, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Estradiol; Isoprostanes; Medroxyprogesterone acetate; Menopause; Oxidative stress; Progesterone

Indexed keywords

ESTRADIOL; ESTRADIOL VALERATE; ISOPROSTANE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; CHOLESTEROL; GESTAGEN; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BEDTIME DOSAGE; BLEEDING; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ESTRADIOL BLOOD LEVEL; FATTY ACID BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OXIDATIVE STRESS; PATHOGENESIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; BLOOD; ESTROGEN THERAPY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHOLESTEROL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; F2-ISOPROSTANES; FEMALE; HUMANS; LIPOPROTEINS; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS;

EID: 51449088411     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31815f8943     Document Type: Article

References (26)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
2. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005;353:9-11.
3. Strehlow K, Rotter S, Wassmann S, et al. Modulation of antioxi-dant enzyme expression and function by estrogen. Circ Res 2003;93: 170-177.
4. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxypro-gesterone acetate on endothelium-dependent vasodilation in postmeno-pausal women receiving estrogen. Circulation 2001;104:1773-1778.
5. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 2005;97:1046-1054.
6. Montuschi P, Barnes P, Roberts LJ 2nd. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007;14:703-717.
7. 2α in the arterial wall layers of various species: a comparison between intact and atherosclerotic areas. Prostaglandins Leukot Essent Fatty Acids 2001;64:167-171.
8. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006;98:9P-17P.
9. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3-63.
10. Rontu R, Solakivi T, Teisala K, Lehtimaki T, Punnonen R, Jokela H. Impact of long-term hormone replacement therapy on in vivo and in vitro markers of lipid oxidation. Free Radic Res 2004;38:129-137.
11. Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy. Climacteric 2006;9:452-458.
12. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283.
13. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
14. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab 1998;83:649-659.
15. McKinney KA, Duell PB, Wheaton DL, et al. Differential effects of subcutaneous estrogen and progesterone on low-density lipoprotein size and susceptibility to oxidation in postmenopausal rhesus monkeys. FertilSteril 1997;68:525-530.
16. 2α-isoprostane production in cultured human endothelial cells. Am J Physiol Heart Circ Physiol 2002;283:H2644-H2649.
17. 2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007;2: 221-226.
18. 4 poisoning? Free Radic Biol Med 2005;38:698-710.
19. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815-1826.
20. 2- isoprostanes in human atherosclerotic lesions. J Clin Invest 1997;100: 2028-2034.
21. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-286.
22. 2α by human platelets on collagen stimulation. Platelets 1999;10:253-256.
23. 2α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109:843-848.
24. Polidori MC, Pratico D, Parente B, et al. Elevated lipid peroxidation biomarkers and low antioxidant status in atherosclerotic patients with increased carotid or iliofemoral intima media thickness. J Investig Med 2007;55:163-167.
25. Cracowski JL, Durand T. Cardiovascular pharmacology and physiology of the isoprostanes. Fundam Clin Pharmacol 2006;20:417-427.
26. 2- isoprostanes as markers of in vivo lipid peroxidation - A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 1999;272:209-215.